International Affiliates

International affiliates hero image

Global partners creating a world without T1D

Achieving our vision of a world without T1D requires global collaboration. Approximately 1.6 million Americans live with type 1 diabetes (T1D), and countless more people are affected by the disease around the world. Our five affiliates—Australia, Canada, Israel, the Netherlands, and the United Kingdom—are pivotal partners in funding the research that will reduce the burden of T1D on people’s lives until there is a cure.

JDRF Australia main image

  JDRF Australia

   Visit JDRF Australia

  • More than 125,000 Australians are currently living with T1D, with 8 more people diagnosed each day
  • Australians with T1D are 5 times more likely to suffer from depression and 1.8 times more likely to suffer from anxiety than someone without T1D
  • T1D costs the Australian economy a total of $2.9 billion annually through a range of direct and indirect costs
  • To date, JDRF Australia has invested more than $266 million into research across diverse focus areas including disease-modifying therapies, screening for T1D, closed-loop insulin delivery, and more
  • JDRF Australia is currently funding more than 50 active research projects across Australia
  • JDRF Australia’s advocacy efforts have been instrumental in producing over half a billion dollars of new investment into type 1 diabetes in Australia in the last 10 years
  • Supported by the Australian Government, JDRF established The Australian Type 1 Diabetes Clinical Research Network (T1DCRN) to forge global partnerships and bring together world class T1D researchers. The T1DCRN is currently funding more than 30 cutting-edge research projects

   Sources:

  • JDRF Cure, Treat, Prevent report, 2019, The Economic Cost of Living with T1D report, 2021, JDRF Financial Reports 2016 – 2020
JDRF Australia collage image

  JDRF Canada

   Visit JDRF Canada

  • In 1974, a group of parents determined to find a cure for their children living with type 1 diabetes (T1D) came together and began JDRF Canada, launching the largest funder and advocate for T1D research in Canada
  • JDRF works every day to change the reality of this disease for millions of people by funding research, advocating for government support of research, new therapies and devices, and connecting the T1D community
  • In 2020 JDRF Canada supported 37 active projects in Canada with a total multi-year grant value of approximately $38 million CDN. Of these projects, 30 percent were clinical trials, and another 30 percent were led by postdoctoral fellows—the next generation of Canadian T1D researchers
  • As many as 300,000 Canadians live with T1D

  JDRF The Netherlands

   Visit JDRF The Netherlands

  • JDRF The Netherlands was founded 10 years ago by Maarten de Groot, father of a son with T1D
  • In The Netherlands, 120,000 people are living with type 1 diabetes; 15,000 of them are children 
  • In 10 years, JDRF spent almost 9 million Euro for scientific research in the Netherlands

  JDRF Israel

   Visit JDRF Israel

  • JDRF Israel is the only nonprofit organization in Israel that is focused solely on people with T1D
  • The organization has partnered with the Israel Science Foundation to establish a $6 million initiative to support T1D research in Israel
  • JDRF Israel serves approximately 50,000 people affected by T1D

  JDRF United Kingdom

   Visit JDRF United Kingdom

  • The UK has one of the highest rates of T1D in the world, with 400,000 people living with the condition
  • Various world leading T1D researchers are based at UK institutions, including Professor Roman Hovorka at the University of Cambridge, who launched the world’s first licensed artificial pancreas app in 2020
  • Former UK Prime Minister, Theresa May, was announced as an ambassador for JDRF UK in 2020
  • JDRF UK set up the Connect Immune Research initiative, alongside Versus Arthritis, the MS Society and the British Society for Immunology, to research the links between different autoimmune conditions and accelerate new treatments and cures. The partnership continues to expand as new organizations representing autoimmune conditions join
  • In June 2021, the National Health Service (NHS) announced a pilot to support the wider roll out of artificial pancreas technology across England for people with type 1 diabetes, following JDRF UK’s advocacy
  • This advocacy operation has also seen all pregnant women with type 1 diabetes in England and Wales provided with continuous glucose monitors via the NHS